Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Multi-Centric, Open-labeled Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose in Participants Previously Vaccinated With EUA Vaccines

NCT05567471 is registered in ClinicalTrials.gov with Bharat Biotech International Limited as lead sponsor.

NCT NCT05567471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05567471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Multi-Centric, Open-labeled Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose in Participants Previously Vaccinated With EUA Vaccines
Lead sponsor
Bharat Biotech International Limited
Phase
Phase 3
Overall status
Completed
Start date
February 26, 2022
Completion date
September 28, 2022
Enrollment
875 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 respiratory infection